Opinion|Videos|September 30, 2024
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Key Takeaways
- NMIBC management includes TURBT and intravesical therapy, with BCG as a key treatment for higher-risk patients.
- BCG treatment stimulates an immune response, enhancing the body's ability to target bladder cancer cells.
Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the standard treatment options for non–muscle-invasive bladder cancer (NMIBC)?
- What are the management options for patients with intermediate and high-risk NMIBC?
- Can you explain the mechanism of action of BCG treatment in stimulating the immune response against bladder cancer?
- In an ideal treatment paradigm with single-agent BCG, what are the best outcomes for patients with high-risk NMIBC?
- What are the rates of recurrence and progression?
- What do you feel the rates of progression are in the real world vs what you see in your practice?
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
3
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5